Arotinolol (
INN, marketed under the tradename Almarl) is a
medication in the class of mixed
alpha/
beta blockers.[1] It also acts as a
β3 receptoragonist.[2] A 1979 publication suggests arotinolol as having first been described in the scientific literature by
Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[3]
^Zhao J, Golozoubova V, Cannon B, Nedergaard J (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Canadian Journal of Physiology and Pharmacology. 79 (7): 585–593.
doi:
10.1139/cjpp-79-7-585.
PMID11478592.
^Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor". Parkinsonism & Related Disorders. 9 (6): 341–347.
doi:
10.1016/S1353-8020(03)00029-4.
PMID12853233.
Arotinolol (
INN, marketed under the tradename Almarl) is a
medication in the class of mixed
alpha/
beta blockers.[1] It also acts as a
β3 receptoragonist.[2] A 1979 publication suggests arotinolol as having first been described in the scientific literature by
Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[3]
^Zhao J, Golozoubova V, Cannon B, Nedergaard J (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Canadian Journal of Physiology and Pharmacology. 79 (7): 585–593.
doi:
10.1139/cjpp-79-7-585.
PMID11478592.
^Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor". Parkinsonism & Related Disorders. 9 (6): 341–347.
doi:
10.1016/S1353-8020(03)00029-4.
PMID12853233.